Low-Grade astrocytomas are the most common cancer of the central nervous system in children. They represent a heterogeneous group of tumors that can be discovered anywhere within the brain or spinal cord. Although surgical resection may be curative, up to 20% of children still suffer from the effects of a tumor, which may result in higher rates of morbidity and mortality. The available treatment options for children are limited in recurrent and/or disseminated, or circulated tumors, as well as those with tumors not suited for surgical resection. To date, this significant, un-met need for more effective, targeted therapeutics for children with unresectable or progressive astrocytomas has not yet been satisfied.
How many participants are enrolled?
Available CBTN Biospecimens
participants with flash-frozen tissue available
participants with match blood
participants with match parental specimens
participants with cerebral spinal fluid
Available CBTN Pre-clinical Models
genomically characterized cell lines with data available
genomically characterized pdx with data available
Projects supported by the CBTN
Data projects supported
Specimen projects supported
What type of data are available?
Delineating Pediatric Glioma Progression Using Single-nuclei Sequencing
Low-grade gliomas are the most prevalent brain cancer among children. While patients with this type of cancer respond well to surgery, the majority experience recurrence after initial resection, requiring additional rounds of treatment that are rarely guided by molecular information. Intra-tumour
LGG, Mixed glial and neuronal tumors
Exploration of IDO1 as a therapeutic target in pediatric central nervous system tumors
Because the immune system can suppress and even eradicate tumor growth, tumor progression in central nervous system (CNS) tumors has been linked to immune evasion strategies. The capability of the immune system to recognize and inhibit the growth of cancer is dependent on its ability to recognize
Medulloblastoma, HGG, LGG, Ependymoma, Glioma
Rishi Ramesh Lulla
Investigating the Immune Response in Pediatric Glioma Subsets
Different tumors have different types of immune responses. We would like to better understand the drivers of this differential response so that we can best treat these tumors.
How do I get access to the specimens?
To request any of the biospecimens, or pre-clinical model please fill out this form.
Request take approx. 3 months and will require review by the scientific committee and MTA.
Need help? Contact us at email@example.com
How do I get access to the data?
To access the data please follow these instructions. Need help? Contact us at firstname.lastname@example.org
You can access processed data today here by simply logging in to PedcBioPortal
You can request raw data by completing this form. The review normally takes 1 week. Once approved you can access the raw data by creating cohorts of interest on the Kids First Data Resource Portal and performing analysis on the cloud in Cavatica
Flash frozen tissue is tissue from a surgical procedure where the tissue is frozen instantly in liquid nitrogen to ensure there is no degradation
Tissue in freezing media is tissue from a surgical procedure where the tissue is frozen 1 degree at a time over a 24-hour period to keep the tissue intact and compatible with regrowing the tumor for testing
Matched blood is blood that is collected from the patient in addition to tissue from the tumor. This blood provides researchers a direct comparison between normal and tumor specimens for this specific patient
Cerebral Spinal Fluid (CFS) is fluid taken from the the nervous system that researchers can use to study brain tumors
Paternal and maternal specimens are specimens taken from the biological parents of the subject. These specimens provide researchers with the ability to compare tumor and normal tissue and predispositions